159 related articles for article (PubMed ID: 32477975)
21. Isoniazid mono-resistant tuberculosis: Time to take it seriously.
Garg K; Saini V; Dhillon R; Agarwal P
Indian J Tuberc; 2019 Apr; 66(2):247-252. PubMed ID: 31151492
[TBL] [Abstract][Full Text] [Related]
22. Prospective study of immunomodulation in osteoarticular tuberculosis non responsive to anti tubercular therapy.
Saurabh ; Sharma BP; Kumar A; Das S; Prasad S
J Clin Orthop Trauma; 2018 Mar; 9(Suppl 1):S1-S9. PubMed ID: 29628691
[TBL] [Abstract][Full Text] [Related]
23. Collaborative Ocular Tuberculosis Study Consensus Guidelines on the Management of Tubercular Uveitis-Report 1: Guidelines for Initiating Antitubercular Therapy in Tubercular Choroiditis.
Agrawal R; Testi I; Mahajan S; Yuen YS; Agarwal A; Kon OM; Barisani-Asenbauer T; Kempen JH; Gupta A; Jabs DA; Smith JR; Nguyen QD; Pavesio C; Gupta V;
Ophthalmology; 2021 Feb; 128(2):266-276. PubMed ID: 32115264
[TBL] [Abstract][Full Text] [Related]
24. Reintroduction of Antituberculous Drugs in Patients with Antituberculous Drug-Related Drug Reaction with Eosinophilia and Systemic Symptoms.
Oh JH; Yun J; Yang MS; Kim JH; Kim SH; Kim S; Choi JH; Yim JJ; Kang HR
J Allergy Clin Immunol Pract; 2021 Sep; 9(9):3442-3449.e3. PubMed ID: 33872812
[TBL] [Abstract][Full Text] [Related]
25. CD4 count and risk of anti-tuberculosis drug-associated cutaneous reactions in HIV-infected Thai patients.
Boonyagars L; Hirunwiwatkul P; Hurst CP
Int J Tuberc Lung Dis; 2017 Mar; 21(3):338-344. PubMed ID: 28225346
[TBL] [Abstract][Full Text] [Related]
26. Non-adherence to anti-tubercular treatment during COVID-19 pandemic in Raipur district Central India.
Jaiswal S; Sharma H; Joshi U; Agrawal M; Sheohare R
Indian J Tuberc; 2022 Oct; 69(4):558-564. PubMed ID: 36460389
[TBL] [Abstract][Full Text] [Related]
27. Clindamycin-induced Maculopapular Exanthema with Preferential Involvement of Striae Distensae: A Koebner phenomenon?
Monteagudo B; Cabanillas M; Iriarte P; Ramírez-Santos A; León-Muinos E; González-Vilas D; Suárez-Amor Ó
Acta Dermatovenerol Croat; 2018 Apr; 26(1):61-63. PubMed ID: 29782303
[TBL] [Abstract][Full Text] [Related]
28. Pattern of adverse drug reactions experienced by tuberculosis patients in a tertiary care teaching hospital in Western Nepal.
P V K; Palaian S; Ojha P; P R S
Pak J Pharm Sci; 2008 Jan; 21(1):51-6. PubMed ID: 18166520
[TBL] [Abstract][Full Text] [Related]
29. Isoniazid Induced Cutaneous Leukocytoclastic Vasculitis in Extra Pulmonary Tuberculosis (Pott's Spine): A Case Report.
Bondalapati S; V DR; Rampure D; S RR
J Clin Diagn Res; 2014 Aug; 8(8):MD03-5. PubMed ID: 25302231
[TBL] [Abstract][Full Text] [Related]
30. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
31. Rifampicin-Induced Concomitant Renal Injury and Hepatitis.
Chogtu B; Surendra VU; Magazine R; Acharya PR; Yerrapragada DB
J Clin Diagn Res; 2016 Sep; 10(9):OD18-OD19. PubMed ID: 27790502
[TBL] [Abstract][Full Text] [Related]
32. Two years review of cutaneous adverse drug reaction from first line anti-tuberculous drugs.
Tan WC; Ong CK; Kang SC; Razak MA
Med J Malaysia; 2007 Jun; 62(2):143-6. PubMed ID: 18705448
[TBL] [Abstract][Full Text] [Related]
33. Tuberculosis of the spine in children - does drug resistance affect surgical outcomes?
Pinto D; Dhawale A; Shah I; Rokade S; Shah A; Chaudhary K; Aroojis A; Mehta R; Nene A
Spine J; 2021 Dec; 21(12):1973-1984. PubMed ID: 34116216
[TBL] [Abstract][Full Text] [Related]
34. Profile and outcome of childhood tuberculosis treated with DOTS--an observational study.
Panigatti P; Ratageri VH; Shivanand I; Madhu PK; Shepur TA
Indian J Pediatr; 2014 Jan; 81(1):9-14. PubMed ID: 23893370
[TBL] [Abstract][Full Text] [Related]
35. Demographic profile, clinical and microbiological predictors of mortality amongst admitted pediatric TB patients in a tertiary referral tuberculosis hospital.
Sharma S; Sarin R; Sahu G; Shukla G
Indian J Tuberc; 2020 Jul; 67(3):312-319. PubMed ID: 32825857
[TBL] [Abstract][Full Text] [Related]
36. An epidemiological study of multi drug resistant tuberculosis cases registered under Revised National Tuberculosis Control Programme of Ahmedabad City.
Bhatt G; Vyas S; Trivedil K
Indian J Tuberc; 2012 Jan; 59(1):18-27. PubMed ID: 22670507
[TBL] [Abstract][Full Text] [Related]
37. Patch-testing for the management of hypersensitivity reactions to second-line anti-tuberculosis drugs: a case report.
Khan S; Andries A; Pherwani A; Saranchuk P; Isaakidis P
BMC Res Notes; 2014 Aug; 7():537. PubMed ID: 25128289
[TBL] [Abstract][Full Text] [Related]
38. Levofloxacin based non-rifampicin anti-tuberculous therapy: An effective alternative in renal transplant recipients in resource limited setting.
Gupta KL; Bagai S; Kumar H; Nayak S; Muthu V; Kumar V; Rathi M; Kohli HS; Sharma A; Ramachandran R
Nephrology (Carlton); 2021 Feb; 26(2):178-184. PubMed ID: 33155329
[TBL] [Abstract][Full Text] [Related]
39. Studies on a new antitubercular drug, trifluoperazine: Its effect in combination with conventional antitubercular drugs in tubercular lymphadenitis.
Gupta RL; Jain S; Talwar V; Gupta HC; Murthy PS
Indian J Clin Biochem; 1998 Jul; 13(2):92-7. PubMed ID: 23105188
[TBL] [Abstract][Full Text] [Related]
40. Six-month therapy for abdominal tuberculosis.
Jullien S; Jain S; Ryan H; Ahuja V
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012163. PubMed ID: 27801499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
